By / December 5, 2019

Canopy Growth continues to focus on the U.S. CBD market

The FDA has recently put a damper on the U.S. CBD market and has been very cautious about new CBD-based products. However, Canopy Growth still has its focus on the United States. is a mobile application that is exclusively dedicated to hemp, cannabis and marijuana news. The application provides you with the latest news from top cannabis sources.

FDA warns about the U.S. CBD market

The FDA recently announced that it does not currently have sufficient data on the safety of CBD-based products. Therefore, it is not possible to declare the U.S. CBD market safe for use by humans and animals.

This caused unrest in the cannabis industry and prompted economists to lower estimates for the U.S. CBD market.

Canopy Growth, however, does not seem to see that as a reason to avoid the market in the south. After all, CBD products are very popular in the U.S. and are legal in 31 states, meanwhile, the Canadian market remains weak.

Canopy Growth enters the U.S. CBD market

Canopy Growth has entered the U.S. CBD market with its own brand.

The “First and Free” brand is to be available in all U.S. states in which CBD is legal. Gels, oils, and creams for external use are to be sold on the U.S. CBD market.

FDA warns about the U.S. CBD market
The FDA announced that the North American CBD market is not safe for humans or animals. (Source)

Canopy Growth has also taken the FDA’s testimony into account and announced on the website that the statements on the products have not been evaluated by the FDA and that the products are not designed to diagnose, treat, cure or prevent disease.

The decline of cannabis stocks

In the past few months, cannabis stocks have seen a considerable decline in some areas. The cannabis industry continues to find it difficult to generate profits, and the Canadian cannabis market, in particular, has been hard on producers.

Analyst Bill Kirk of MKM recently announced that Canopy Growth is expected to post EPS losses by 2022.

Kirk stated that current spending is only the beginning of what is needed to take advantage of profitable opportunities in the future. The existing agribusiness is expected to remain under pressure with supply growth.

Canopy Growth’s brand differentiation

Weed growing in the U.S. CBD market.
Stocks have experienced variations as the cannabis business pushes for more supply. (Source)

It is also difficult for Canopy Growth to differentiate its own brands on the U.S. CBD market. However, the company could benefit from the comparatively better R&D measures made possible by Constellation Brands’ involvement.

“We have built our hemp supply chain in the United States through partnering with a diverse group of contract farmers and manufacturers across several states for the cultivation, extraction, processing, and production of hemp-derived products,” the company said in the financial documents released last month.


(Featured image by Enecta Cannabis extracts via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in shareribs, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.